Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

INMB

INmune Bio Inc

1.61

Jul 07 • 09:44AM ET -0.06 (-3.35%)

Healthcare Biotechnology USA Nano NASD

Peers: ATOS LTRN NTRB OTLK QNTM RNXT XLO GLSI RZLT TLPH

| Held by: VTI VXF VTWO IWC VTWG

Scroll to Statements

Index	-
Market Cap	42.78M
Enterprise Value	22.93M
Income	-41.60M
Sales	0.00M
Book/sh	0.74
Cash/sh	0.80
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Feb 04, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.18
P/C	2.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.24
Current Ratio	4.24
Debt/Eq	0.08
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-1.69
EPS next Y	-0.76
EPS next Q	-0.19
EPS this Y	62.23%
EPS next Y	-7.71%
EPS next 5Y	35.46%
EPS past 3/5Y	-6.80% -12.95%
Sales past 3/5Y	-48.87% 35.58%
EPS Y/Y TTM	13.12%
Sales Y/Y TTM	-100.00%
EPS Q/Q	53.01%
Sales Q/Q	-100.00%
Earnings	May 07 AMC
EPS/Sales Surpr.	18.37% -

Insider Own	11.17%
Insider Trans	0.00%
Inst Own	20.22%
Inst Trans	0.96%
ROA	-130.78%
ROE	-168.78%
ROIC	-203.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.91%
SMA50	12.59%
SMA200	3.30%
Trades

Shs Outstand	26.59M
Shs Float	23.62M
Short Float	15.53%
Short Ratio	5.71
Short Interest	3.67M
52W High	3.24 -50.39%
52W Low	1.09 47.63%
Volatility	9.48% 8.70%
ATR (14)	0.12
RSI (14)	59.75
Beta	0.99
Rel Volume	1.98
Avg Volume	642.99K
Volume	106,956

Perf Week	-0.67%
Perf Month	19.20%
Perf Quarter	30.83%
Perf Half Y	4.49%
Perf YTD	3.15%
Perf Year	-30.03%
Perf 3Y	-83.08%
Perf 5Y	-91.85%
Perf 10Y	-
Recom	1.00
Target Price	7.00
Prev Close	1.66
Price	1.61
Change	-3.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform	$0.60
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$23
Oct-21-24	Initiated	Alliance Global Partners	Buy	$20
Sep-27-24	Initiated	Raymond James	Outperform	$18
Aug-22-24	Initiated	Scotiabank	Sector Outperform	$22
Jun-01-23	Initiated	Robert W. Baird	Outperform	$16
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral	$14 → $7
Jul-07-21	Reiterated	Maxim Group	Buy	$32 → $42
Apr-21-21	Initiated	B. Riley Securities	Buy	$29
Jan-22-21	Reiterated	Maxim Group	Buy	$16 → $32
Sep-01-20	Initiated	BTIG Research	Buy	$23
Jul-15-20	Reiterated	H.C. Wainwright	Buy	$7 → $20

Show Previous Ratings

Jul-01-26 07:00AM	INmune Bio Advances CORDStrom Platform Patent Application in the U.S. Following Favorable International Written Opinion (GlobeNewswire)
Jun-25-26 07:00AM	INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom (GlobeNewswire) +10.37%
Jun-23-26 08:00AM	INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom in RDEB (GlobeNewswire)
Jun-02-26 08:00AM	INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial (GlobeNewswire)
May-19-26 09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire) -5.37%
08:00AM	Loading…
May-15-26 08:00AM	INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform (GlobeNewswire) -7.74%
May-14-26 08:00AM	INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease (GlobeNewswire) +15.07%
May-13-26 08:00AM	INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point (GlobeNewswire) +5.04%
May-08-26 08:30AM	INmune Bio, Inc. Q1 2026 Earnings Call Summary (Moby)
May-07-26 04:00PM	INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update (GlobeNewswire) -5.92%
May-05-26 04:00PM	INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases (GlobeNewswire)
Apr-30-26 08:00AM	INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th (GlobeNewswire) +7.52%
Apr-16-26 08:00AM	INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models (GlobeNewswire)
Mar-31-26 08:30AM	INmune Bio, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-30-26 11:01PM	INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
04:00PM	Loading…
04:00PM	INmune Bio Inc. Announces 2025 Results and Provides Business Update (GlobeNewswire)
Mar-24-26 08:00AM	INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. (GlobeNewswire)
Mar-19-26 08:00AM	INmune Bio's MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer's Disease (GlobeNewswire)
Mar-11-26 06:11AM	INmune Bio upgraded to Buy from Neutral at Lucid Capital (TipRanks) +10.94%
Feb-23-26 09:25AM	INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar (GlobeNewswire)
Feb-19-26 12:15PM	INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom for RDEB (GlobeNewswire)
Feb-12-26 07:00AM	INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's Disease (GlobeNewswire) -6.37%
Feb-11-26 08:12AM	INmune Bio submits pre-submission package for CORDStrom with MHRA (TipRanks)
Feb-10-26 08:00AM	INmune Bio Advances CORDStrom Towards UK Marketing Authorization in RDEB (GlobeNewswire)
Jan-27-26 09:25AM	INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives (GlobeNewswire) +7.78%
Dec-05-25 07:00AM	Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom Platform (GlobeNewswire)
Dec-01-25 08:00AM	INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients (GlobeNewswire) -10.06%
Nov-18-25 08:00AM	INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference (GlobeNewswire)
Nov-06-25 09:55AM	INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) -7.91%
Oct-30-25 11:03PM	INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ... (GuruFocus.com) +5.78%
04:05PM	Loading…
04:05PM	INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update (GlobeNewswire)
Oct-23-25 07:00AM	INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 (GlobeNewswire)
Oct-14-25 07:00AM	INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 (GlobeNewswire)
Sep-29-25 08:00AM	INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal (GlobeNewswire)
Sep-15-25 08:00AM	INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom at CGT Catapult (GlobeNewswire)
Sep-08-25 04:50PM	INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -7.18%
Aug-07-25 04:05PM	INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes (GlobeNewswire) -8.24%
Aug-04-25 08:00AM	INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment (GlobeNewswire) +11.52%
Jul-31-25 07:00AM	INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th (GlobeNewswire)
Jul-29-25 07:00AM	INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro Presented at the Alzheimer's Association International Conference (GlobeNewswire) +8.59%
Jul-24-25 07:00AM	INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimer's Association International Conference (GlobeNewswire)
Jul-01-25 01:37PM	INmune slides again as Scotiabank, RJ cut ratings after Alzheimers drug miss (Investing.com) -9.52%
Jun-30-25 04:05PM	INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -56.66%
08:16AM	INmune Bio stock plummets after mixed Phase 2 Alzheimers trial results (Investing.com)
07:30AM	INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro in Early Alzheimer's Disease (GlobeNewswire)
Jun-27-25 12:16PM	INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -15.13%
Jun-26-25 04:00PM	INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th (GlobeNewswire) -14.79%
Jun-10-25 04:00PM	XPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense (GlobeNewswire)
May-14-25 08:00AM	INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) -7.82%
May-08-25 04:10PM	INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update (GlobeNewswire)
May-07-25 11:23AM	INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-05-25 07:00AM	INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th (GlobeNewswire)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-16-25 07:00AM	INmune Bio Receives Favorable Patentability Opinion for CORDStrom Platform Technology (GlobeNewswire)
Apr-15-25 07:42AM	INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms (Pharmaceutical Business Review)
Apr-14-25 08:00AM	INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom Manufacturing for Commercial Readiness (GlobeNewswire)
Apr-01-25 07:00AM	INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study (GlobeNewswire)
Mar-28-25 03:04AM	INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Mar-27-25 08:15PM	INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update (GlobeNewswire)
Mar-24-25 08:00AM	INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-21-25 01:15PM	Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + (SeekingAlpha)
Mar-02-25 09:28AM	Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-12-25 09:51AM	INmune Bio price target raised to $23 from $22 at Scotiabank (TipRanks) +10.67%
07:00AM	INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer (GlobeNewswire)
Feb-10-25 07:00AM	INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Feb-03-25 08:11PM	Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 (Insider Monkey)
Jan-28-25 08:00AM	INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans (GlobeNewswire)
Jan-12-25 06:05AM	Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks (TipRanks)
Dec-10-24 08:00AM	INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt (GlobeNewswire)
Dec-04-24 02:51PM	OmniScience and INmune Bio Partner for Alzheimers Trial (Exec Edge)
09:00AM	OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower (Business Wire)
Nov-13-24 09:00AM	INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Nov-01-24 11:01AM	INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... (GuruFocus.com)
Oct-31-24 04:05PM	INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Oct-30-24 09:22AM	INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.56%
Oct-28-24 08:00AM	INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB (GlobeNewswire) +13.75%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares (GuruFocus.com)
Oct-24-24 03:03PM	INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro Promotes Remyelination (GlobeNewswire)
09:30AM	INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 (GlobeNewswire)
Oct-11-24 08:30AM	INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-09-24 03:51PM	INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 08:00AM	INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Sep-26-24 08:00AM	INKmune Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort (GlobeNewswire)
Sep-17-24 08:30AM	INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints (GlobeNewswire)
Sep-13-24 08:30AM	INmune Bio Announces $13.0 Million Registered Direct Offering (GlobeNewswire) -14.55%
Sep-03-24 09:00AM	INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference (GlobeNewswire) -7.10%
Aug-01-24 04:05PM	INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update (GlobeNewswire) -7.92%
Jul-29-24 09:00AM	INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro on Proteins that Regulation Synapses in Alzheimer's Patients (GlobeNewswire)
Jul-25-24 08:00AM	INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 (GlobeNewswire)
Jul-23-24 08:45AM	INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Jun-28-24 12:13PM	INmune Bios unique Alzheimers trial endpoint receives validation (Clinical Trials Arena)
Jun-27-24 08:00AM	INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial (GlobeNewswire) +19.20%
May-30-24 08:00AM	INmune Bio Inc. to Join Russell 3000 Index (GlobeNewswire)
May-13-24 11:54AM	INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:05PM	INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update (GlobeNewswire) -6.96%
May-07-24 08:00AM	INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 (GlobeNewswire)
Apr-30-24 08:00AM	INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years (GlobeNewswire)
Apr-29-24 08:00AM	INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Apr-25-24 09:00AM	INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer's disease. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

PresidentMr. David J. Moss M.B.A.

Interim Chief Financial OfficerMr. Cory Randall Ellspermann

Chief Scientific Officer & Chief Manufacturing OfficerDr. Mark William Lowdell Ph.D.

Head of Investor RelationsMr. Daniel Frederick Carlson

General CounselMr. Joshua S. Schoonover Esq.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Juda Scott	Director	Jul 02 '26	Option Exercise	1.40	14,801	20,721	86,404	Jul 07 07:01 AM
Lowdell Mark William	Chief Scientific Officer	Jul 02 '26	Option Exercise	1.40	7,211	10,095	1,518,017	Jul 07 07:01 AM
Moss David J	Chief Executive Officer	Jul 02 '26	Option Exercise	1.40	9,014	12,620	1,294,883	Jul 07 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INMB

INmune Bio Inc

Upgrade your Finviz experience